Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo in Relapsed/Refractory Hematologic Malignancies Post CAR-T
NCT04205409Phase 2Completed
- Sponsor
- University of Washington
- Start
- Jun 2020
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), sponsored by University of Washington. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04205409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205409.